Show simple item record

Authordc.contributor.authorHerrera Zelada, Nicolás Gabriel
Authordc.contributor.authorZúñiga Cuevas, Úrsula Almendra
Authordc.contributor.authorRamírez Reyes, Andrés Ignacio
Authordc.contributor.authorLavandero González, Sergio
Authordc.contributor.authorRiquelme Meléndez, Jaime
Admission datedc.date.accessioned2021-10-25T20:48:10Z
Available datedc.date.available2021-10-25T20:48:10Z
Publication datedc.date.issued2021
Cita de ítemdc.identifier.citationFrontiers in Pharmacology February 2021 | Volume 12 | Article 636134es_ES
Identifierdc.identifier.other10.3389/fphar.2021.636134
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/182385
Abstractdc.description.abstractDespite considerable improvements in the treatment of myocardial infarction, it is still a highly prevalent disease worldwide. Novel therapeutic strategies to limit infarct size are required to protect myocardial function and thus, avoid heart failure progression. Cardioprotection is a research topic with significant achievements in the context of basic science. However, translation of the beneficial effects of protective approaches from bench to bedside has proven difficult. Therefore, there is still an unmet need to study new avenues leading to protecting the myocardium against infarction. In line with this, the endothelium is an essential component of the cardiovascular system with multiple therapeutic targets with cardioprotective potential. Endothelial cells are the most abundant non-myocyte cell type in the heart and are key players in cardiovascular physiology and pathophysiology. These cells can regulate vascular tone, angiogenesis, hemostasis, and inflammation. Accordingly, endothelial dysfunction plays a fundamental role in cardiovascular diseases, which may ultimately lead to myocardial infarction. The endothelium is of paramount importance to protect the myocardium from ischemia/reperfusion injury via conditioning strategies or cardioprotective drugs. This review will provide updated information on the most promising therapeutic agents and protective approaches targeting endothelial cells in the context of myocardial infarction.es_ES
Patrocinadordc.description.sponsorshipAgencia Nacional de Investigacion y Desarrollo (ANID, Chile) FONDAP 15130011 FONDECYT 1200490 FONDECYT 11181000es_ES
Lenguagedc.language.isoenes_ES
Publisherdc.publisherFrontiers Mediaes_ES
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
Sourcedc.sourceFrontiers in Pharmacologyes_ES
Keywordsdc.subjectCardioprotectiones_ES
Keywordsdc.subjectEndotheliumes_ES
Keywordsdc.subjectIschemiaes_ES
Keywordsdc.subjectReperfusiones_ES
Keywordsdc.subjectEndothelial cellses_ES
Keywordsdc.subjectMyocardial infarctiones_ES
Keywordsdc.subjectSmall extracellular vesicleses_ES
Títulodc.titleTargeting the Endothelium to Achieve Cardioprotectiones_ES
Document typedc.typeArtículo de revistaes_ES
dc.description.versiondc.description.versionVersión publicada - versión final del editores_ES
dcterms.accessRightsdcterms.accessRightsAcceso abiertoes_ES
Catalogueruchile.catalogadorcrbes_ES
Indexationuchile.indexArtículo de publícación WoSes_ES


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States